Will Tesla Go Up or Down in 2025?
The last few months have been exciting for Tesla and…
Sell
35
EYPT Quote, Financials, Valuation and Earnings
Last price:
$7.20
Seasonality move
:
6.71%
Day range:
$7.19 - $7.74
52-week range:
$6.90 - $30.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.98x
P/B ratio:
2.25x
Volume:
673.6K
Avg. volume:
976.7K
1-year change:
-70.16%
Market cap:
$491.4M
Revenue:
$46M
EPS (TTM):
-$1.99
Analysts' Opinion
-
Consensus RatingEyePoint Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $33.45, EyePoint Pharmaceuticals has an estimated upside of 364.65% from its current price of $7.20.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $18.00 representing 100% downside risk from its current price of $7.20.
Fair Value
-
According to the consensus of 8 analysts, EyePoint Pharmaceuticals has 364.65% upside to fair value with a price target of $33.45 per share.
EYPT vs. S&P 500
-
Over the past 5 trading days, EyePoint Pharmaceuticals has overperformed the S&P 500 by 0.45% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
EyePoint Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
EyePoint Pharmaceuticals revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter EyePoint Pharmaceuticals reported revenues of $10.5M.
Earnings Growth
-
EyePoint Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter EyePoint Pharmaceuticals reported earnings per share of -$0.54.
Enterprise value:
237.6M
EV / Invested capital:
1.09x
Price / LTM sales:
7.98x
EV / EBIT:
--
EV / Revenue:
5.20x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.01x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$41.8M
Return On Assets:
-35.24%
Net Income Margin (TTM):
-226.57%
Return On Equity:
-50.67%
Return On Invested Capital:
-50.67%
Operating Margin:
-311.18%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $42.4M | $42.5M | $45.7M | $15.2M | $10.5M | |
| Gross Profit | $34.5M | $35.5M | $41.8M | $14M | $9.8M | |
| Operating Income | -$73.9M | -$81.7M | -$117M | -$14.4M | -$32.7M | |
| EBITDA | -$71.6M | -$97.4M | -$102.3M | -$12.5M | -$29M | |
| Diluted EPS | -$2.16 | -$2.66 | -$1.99 | -$0.33 | -$0.54 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $47.6M | $141.8M | $192.1M | $150.2M | $268.5M | |
| Total Assets | $76.8M | $168.3M | $220.5M | $160M | $300.9M | |
| Current Liabilities | $12.9M | $19.9M | $34.3M | $63.9M | $48.8M | |
| Total Liabilities | $69.2M | $75.5M | $84.1M | $101.4M | $82.2M | |
| Total Equity | $7.6M | $92.7M | $136.4M | $58.6M | $218.7M | |
| Total Debt | $50.8M | $36.4M | $39.7M | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$69.1M | $12.4M | -$113.5M | -$15.2M | -$39M | |
| Cash From Investing | -$83.1M | $76.8M | -$170.5M | -$1.7M | $16.2M | |
| Cash From Financing | $107.9M | -$31.5M | $230.8M | $10.4M | $11.9M | |
| Free Cash Flow | -$70.7M | $9.2M | -$118M | -$16.9M | -$40.6M | |
EYPT
Sector
Market Cap
$491.4M
$45.9M
Price % of 52-Week High
23.23%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-70.16%
-32.15%
Beta (5-Year)
1.455
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$7.38
200-day SMA
Sell
Level
$11.31
Bollinger Bands (100)
Sell
Level
7.73 - 10.35
Chaikin Money Flow
Sell
Level
-210.5M
20-day SMA
Sell
Level
$7.95
Relative Strength Index (RSI14)
Sell
Level
37.40
ADX Line
Buy
Level
23.32
Williams %R
Buy
Level
-87.1245
50-day SMA
Sell
Level
$9.48
MACD (12, 26)
Sell
Level
-0.59
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
107M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.1628)
Sell
CA Score
(Annual)
Level (-0.754)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (0.7732)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Stock Forecast FAQ
In the current month, EYPT has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EYPT average analyst price target in the past 3 months is $33.45.
-
Where Will EyePoint Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that EyePoint Pharmaceuticals share price will rise to $33.45 per share over the next 12 months.
-
What Do Analysts Say About EyePoint Pharmaceuticals?
Analysts are divided on their view about EyePoint Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that EyePoint Pharmaceuticals is a Sell and believe this share price will drop from its current level to $18.00.
-
What Is EyePoint Pharmaceuticals's Price Target?
The price target for EyePoint Pharmaceuticals over the next 1-year time period is forecast to be $33.45 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EYPT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for EyePoint Pharmaceuticals is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of EYPT?
You can purchase shares of EyePoint Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase EyePoint Pharmaceuticals shares.
-
What Is The EyePoint Pharmaceuticals Share Price Today?
EyePoint Pharmaceuticals was last trading at $7.20 per share. This represents the most recent stock quote for EyePoint Pharmaceuticals. Yesterday, EyePoint Pharmaceuticals closed at $7.20 per share.
-
How To Buy EyePoint Pharmaceuticals Stock Online?
In order to purchase EyePoint Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Coinbase Stock Going Down?
Every way you look at it, Coinbase has had a…
Is Uber Stock a Buy on the Dip?
Shares of Uber Technologies (NYSE:UBER) have been fading fast in…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 28
Lemonade [LMND] is down 10.69% over the past day.
Sell
50
TSLL alert for Dec 28
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.
Buy
63
SMLR alert for Dec 28
Semler Scientific [SMLR] is down 9.65% over the past day.
